novo nordisk - Search News

Novo Nordisk’s Ozempic Gets FDA Approval

Reuters on MSN · 1h

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

The Wall Street Journal on MSN · 4h

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

U.S. News & World Report · 4h

US FDA Approves Novo Nordisk's Diabetes Drug to Reduce Risk of Worsening Kidney Disease

(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

Novo Nordisk settles Minnesota insulin pricing case

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.

MN Novo Nordisk settlement over insulin pricing [RAW]

Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The settlement requires Novo Nordisk to offer its insulin products to Minnesotans for no more than $35 a month over the next five years.

2h

Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Outsourcing-pharma10h

Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

1d

Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

4d

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results